Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer.
暂无分享,去创建一个
Agnieszka Szymczyk | M. Bryś | E. Forma | W. Różański | A. Krześlak | Ewa Forma | Grażyna Chwatko | Anna Krześlak | Magdalena Bryś | Paweł Jóźwiak | Jacek Wilkosz | Waldemar Różański | G. Chwatko | Paweł Jóźwiak | J. Wilkosz | A. Szymczyk | Jacek Wilkosz
[1] D. Giedroc,et al. Metal response element (MRE)-binding transcription factor-1 (MTF-1): structure, function, and regulation. , 2001, Antioxidants & redox signaling.
[2] J. Koropatnick,et al. Signaling events for metallothionein induction. , 2003, Mutation research.
[3] A. Schäffer,et al. Biochemistry of metallothionein. , 1988, Biochemistry.
[4] P. Coyle,et al. Metallothionein: the multipurpose protein , 2002, Cellular and Molecular Life Sciences CMLS.
[5] P. Dzięgiel. Expression of metallothioneins in tumor cells. , 2004, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[6] H. Gurer,et al. Can antioxidants be beneficial in the treatment of lead poisoning? , 2000, Free radical biology & medicine.
[7] B. Jiao,et al. Metallothionein gene expression under different time in testicular Sertoli and spermatogenic cells of rats treated with cadmium. , 2003, Reproductive toxicology.
[8] T. Rohan,et al. Trace elements and cancer risk: a review of the epidemiologic evidence , 2007, Cancer Causes & Control.
[9] V. Saba,et al. Novel -209A/G MT2A Polymorphism in Old Patients with Type 2 Diabetes and Atherosclerosis: Relationship with Inflammation (IL-6) and Zinc , 2005, Biogerontology.
[10] B. Diwan,et al. Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[11] Mutsushi Yamasaki,et al. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. , 2007, Oncology reports.
[12] P. Joseph. Mechanisms of cadmium carcinogenesis. , 2009, Toxicology and applied pharmacology.
[13] M. Webber,et al. Cadmium-induced malignant transformation of human prostate epithelial cells. , 2001, Cancer research.
[14] R. Franklin,et al. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. , 2005, Mitochondrion.
[15] A. Jayasurya,et al. Metallothioneins in human tumors and potential roles in carcinogenesis. , 2003, Mutation research.
[16] A. Daragó,et al. Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions , 2009, BioMetals.
[17] S. Álvarez,et al. Morphological changes and oxidative stress in rat prostate exposed to a non-carcinogenic dose of cadmium. , 2004, Toxicology letters.
[18] M. Stoltenberg,et al. The role of metallothionein in oncogenesis and cancer prognosis. , 2009, Progress in histochemistry and cytochemistry.
[19] L. Patrick. Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. , 2006, Alternative medicine review : a journal of clinical therapeutic.
[20] S. Zaichick,et al. Trace elements of normal, benign hypertrophic and cancerous tissues of the human prostate gland investigated by neutron activation analysis. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[21] M. Webber,et al. Tumor Suppressor Gene Inactivation during Cadmium-Induced Malignant Transformation of Human Prostate Cells Correlates with Overexpression of de Novo DNA Methyltransferase , 2007, Environmental health perspectives.
[22] Antonia A. Nemec,et al. Nickel mobilizes intracellular zinc to induce metallothionein in human airway epithelial cells. , 2009, American journal of respiratory cell and molecular biology.
[23] Z. Kayaaltı,et al. The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels? , 2012, International Archives of Occupational and Environmental Health.
[24] F. Karatas,et al. Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer , 2006, Clinical chemistry and laboratory medicine.
[25] M. Vašák. Advances in metallothionein structure and functions. , 2005, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.
[26] C. Nag,et al. Familial, Environmental, and Occupational Risk Factors in Development of Amyotrophic Lateral Sclerosis , 2012, North American journal of medical sciences.
[27] M. Kondoh,et al. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. , 2002, The Tohoku journal of experimental medicine.
[28] Z. Kayaaltı,et al. Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. , 2010, Toxicology and applied pharmacology.
[29] M. Chatterjee,et al. A Review of Metallothionein Isoforms and their Role in Pathophysiology , 2011, World journal of surgical oncology.
[30] D. Winge,et al. Distinct metal-binding configurations in metallothionein. , 1985, The Journal of biological chemistry.
[31] Z. Kayaaltı,et al. The potential effect of metallothionein 2A -5A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. , 2011, Toxicology and applied pharmacology.
[32] A. Kajdacsy-Balla,et al. Analysis of iron, zinc, selenium and cadmium in paraffin-embedded prostate tissue specimens using inductively coupled plasma mass-spectrometry. , 2008, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.
[33] M. Bryś,et al. Zinc and cadmium analysis in human prostate neoplasms , 2007, Biological Trace Element Research.
[34] A. Hartwig,et al. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms , 2008, Archives of Toxicology.
[35] G. Andrews,et al. The DNA Binding Activity of Metal Response Element-binding Transcription Factor-1 Is Activated in Vivo and in Vitro by Zinc, but Not by Other Transition Metals* , 1998, The Journal of Biological Chemistry.
[36] C. Klaassen,et al. Relative in vitro affinity of hepatic metallothionein for metals. , 1984, Toxicology letters.
[37] R. Franklin,et al. Zinc as an anti-tumor agent in prostate cancer and in other cancers. , 2007, Archives of biochemistry and biophysics.
[38] Z. Arbieva,et al. Analysis of lead toxicity in human cells , 2012, BMC Genomics.
[39] M. Yaman. Comprehensive comparison of trace metal concentrations in cancerous and non-cancerous human tissues. , 2006, Current medicinal chemistry.
[40] T Theophanides,et al. Copper and carcinogenesis. , 2002, Critical reviews in oncology/hematology.
[41] N. Miura,et al. Potential effect on cellular response to cadmium of a single-nucleotide A → G polymorphism in the promoter of the human gene for metallothionein IIA , 2006, Human Genetics.
[42] E. Mariani,et al. The +838 C/G MT2A Polymorphism, Metals, and the Inflammatory/Immune Response in Carotid Artery Stenosis in Elderly People , 2007, Molecular medicine.
[43] M. Yaman,et al. Comparison of trace metal concentrations in malign and benign human prostate. , 2005, Journal of medicinal chemistry.
[44] D. Breljak,et al. Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs , 2010, BioMetals.
[45] S. Theocharis,et al. Expression of metallothionein in lung carcinoma: correlation with histological type and grade , 2002, Histopathology.
[46] M. Bryś,et al. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population. , 2012, Cancer genetics.